Skip to content

Efficacy and Safety of Fentanyl for Pain Control in Newborn on Mechanical Ventilation

Efficacy and Safety of Fentanyl for Pain Control in Newborns on Mechanical Ventilation

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04937946
Enrollment
40
Registered
2021-06-24
Start date
2021-08-01
Completion date
2022-07-01
Last updated
2021-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical Ventilation Complication

Brief summary

The purpose of the study is to assess the efficacy and safety of Fentanyl for pain control in Newborns on mechanical ventilator.

Detailed description

This Randomized Controlled Trial will be conducted in the Department of Neonatology, BSMMU, Dhaka after approval by Institutional Review Board (IRB). A Written informed consent will be obtained before enrollment in the study from the parents or guardians. . The study cohort will comprise all inborn and outborn newborns admitted to the neonatal intensive care unit (NICU) who receive mechanical ventilation administered through an endotracheal tube . The enrolled neonates will be randomly assigned with computer-generated random number tables via software named 'Random Allocation Software', to receive either of the intervention. Once the parents will agree to the study and provide signed informed consent, all eligible neonates will be randomized to start treatment within 24 hours from the initiation of mechanical ventilation. Randomized infants will be allocated to the fentanyl group to receive a continuous infusion of fentanyl or to the placebo group to receive a continuous infusion of iv fluid. Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .

Interventions

DRUGFentanyl

Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .

Sponsors

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Hours to 1 Months
Healthy volunteers
Yes

Inclusion criteria

1. All inborn and outborn newborns admitted to the neonatal intensive care unit (NICU) who received mechanical ventilation administered through an endotracheal tube. 2. Newborn on mechanical ventilator for at least 72 hours.

Exclusion criteria

1. Known genetic or chromosomal disorders, 2. The need for postoperative analgesic therapy during the study period, 3. Major congenital anomaly, 4. Those who received drugs like midazolam, paracetamol, morphine, muscle relaxants, phenobarbital, phenytoin, and chloral hydrate during the study period. 5. Probable rapid extubation.

Design outcomes

Primary

MeasureTime frameDescription
Decrease in Neonatal Pain Agitation and Sedation Scale (NPASS) score.5 daysIf fentanyl is able to decrease NPASS pain score. Total score is 13. A mean difference of 3 points will be considered clinically relevant.

Secondary

MeasureTime frameDescription
Adverse effects of fentanyl5 daysDuration of mechanical ventilation (hours); chest wall rigidity (evaluated by clinical observation), diuresis, hypotension

Contacts

Primary ContactKundan Dr Kundan Kumar Yadav, Resident
kundanyadav1111@gmail.com+8801782443116
Backup ContactDr Sadeka Choudhury Moni, A. Professor
sadeka.moni.08@gmail.com+8801716294371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026